TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin is an anti-CD30 monoclonal antibody-drug coupling approved for the treatment of relapsed or refractory Hodgkin’s lymphoma (Matthys et al., 2024; Oak and Bartlett, 2016).